← All trials
NCT05311709
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2022
- Primary completion
- Oct 1, 2024
- Completion date
- Mar 1, 2025
- First posted
- Apr 5, 2022
- Last posted
- Jun 2, 2022
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vestre Viken Ringerike SykehusLead sponsor
- Aarhus UniversityCollaborator
- Norwegian University of Science and TechnologyCollaborator
- University Hospital of North NorwayCollaborator
- University of OsloCollaborator
- University of Southern DenmarkCollaborator
- University of BergenCollaborator
- University of CopenhagenCollaborator
- Karolinska InstituteCollaborator
- Vestre Viken Ringerike SykehusOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.